Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | LTA4H | P09960 | 2/20 | 0.34 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16291133 | 0.68 | L3MBTL1 (0.57) | KDM4EHPGDALDH1A1MEN1MAPT | |
| SCHEMBL3545 | 0.68 | L3MBTL1 (0.57) | KDM4EHPGDALDH1A1MEN1MAPT | |
| Pyrrole SCHEMBL28839158 | 0.66 | DPP4 (0.50) | KDM4EHPGDALDH1A1MEN1MAPT | |
| SCHEMBL30398774 | 0.66 | L3MBTL1 (0.55) | KDM4EHPGDALDH1A1MEN1MAPT | |
| Fluoride SCHEMBL491501 | 0.66 | L3MBTL1 (0.55) | KDM4EHPGDALDH1A1MEN1MAPT | |
| SCHEMBL29776515 | 0.66 | L3MBTL1 (0.55) | KDM4EHPGDALDH1A1MEN1MAPT | |
| Benzene SCHEMBL28420098 | 0.66 | L3MBTL1 (0.55) | KDM4EHPGDALDH1A1MEN1MAPT | |
| Benzene SCHEMBL29089513 | 0.66 | L3MBTL1 (0.55) | KDM4EHPGDALDH1A1MEN1MAPT | |
| Hydrogen Sulfide SCHEMBL22588115 | 0.66 | L3MBTL1 (0.55) | KDM4EHPGDALDH1A1MEN1MAPT | |
| Ammonia Solution, Strong SCHEMBL34467257 | 0.66 | L3MBTL1 (0.55) | KDM4EHPGDALDH1A1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116354862-A | Substituted azacyclic compounds and application thereof in medicines | 广东东阳光药业有限公司 | 2023-06-30 | — | — | CN | claimed |
| US-20210129125-A1 | PROCESS FOR OLIGOMERIZATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-05-06 | — | — | US | claimed |
| US-7598245-B2 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-06 | — | — | US | claimed |
| US-20080096901-A1 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2008-04-24 | — | — | US | claimed |
| WO-2008033455-A2 | BIPHENYL AND HETEROARYL PHENYL DERIVATIVES AS PROTEIN TYROSINE PHOSPHATASES INHIBITORS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2008-03-20 | — | — | WO | claimed |
| WO-2005037797-A1 | SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | claimed |
| US-20050032792-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | US | claimed |
| US-20030225270-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | US | claimed |
| US-6649642-B2 | Useful in the treatment of autoimmune and other cathepsin related diseases. | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-11-18 | — | — | US | claimed |
| JP-2003529546-A | — | — | 2003-10-07 | — | — | JP | claimed |
| EP-1218372-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2002-07-03 | — | — | EP | claimed |
| US-20020058809-A1 | Compounds useful as reversible inhibitors of cysteine proteases | EMMANUEL MICHEL JOSE (US) | 2002-05-16 | — | — | US | claimed |
| EP-1204652-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-05-15 | — | — | EP | claimed |
| US-20010041700-A1 | Novel succinate derivative compounds useful as cysteine protease inhibitors | BEKKALI YOUNES (US) | 2001-11-15 | — | — | US | claimed |
| US-6313117-B1 | TREATING AUTOIMMUNE DISORDERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | claimed |
| WO-2001019816-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | claimed |
| WO-2001009110-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | claimed |
| EP-0612743-B1 | Oxazolidinedione derivatives, their production and use in lowering blood sugar and lipid levels | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-09-10 | — | — | EP | claimed |
| EP-0261755-B1 | FIVE-MEMBERED HETEROCYCLIC DERIVATIVES OF N'-SUBSTITUTED-N,N'-DIACYLHYDRAZINES | ROHM AND HAAS COMPANY (US) | 1992-12-16 | — | — | EP | claimed |
| EP-0261755-A2 | Five-membered heterocyclic derivatives of N'-substituted-N,N'-Diacylhydrazines | ROHM AND HAAS COMPANY (US) | 1988-03-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210129125-A1 | PROCESS FOR OLIGOMERIZATION | OXER1, NOD1, LIG1 | KDM4E 2748/4885HPGD 1214/4885ALDH1A1 4182/4885 |
| US-20020058809-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | KDM4E 3983/4885HPGD 1504/4885ALDH1A1 1811/4885 |
| US-20080096901-A1 | Aminotriazole compounds useful as inhibitors of protein kinases | MAP3K20, MAP3K5, MAP3K1 | KDM4E 1081/4885HPGD 3052/4885ALDH1A1 4076/4885 |
| US-20030225270-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | KDM4E 3983/4885HPGD 1504/4885ALDH1A1 1811/4885 |
| US-20050032792-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | KDM4E 3824/4885HPGD 1371/4885ALDH1A1 1878/4885 |
| US-20010041700-A1 | Novel succinate derivative compounds useful as cysteine protease inhibitors | SDHA, LONP1, SUCNR1 | KDM4E 2752/4885HPGD 301/4885ALDH1A1 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.